Antiviral Drugs Market to Reach USD 127 Billion by 2035, Growing at 6.1% CAGR | Gilead Sciences, Pfizer, AbbVie

The global antiviral drugs market, valued at USD 69 billion in 2025, will reach USD 74 billion in 2026 and climb to USD 127 billion by 2035, advancing at a CAGR of 6.1% over the forecast period. Infectious disease burden, accelerating R&D pipelines, and the post-pandemic push for novel antivirals are collectively reshaping this market into one of the pharmaceutical sector's most active growth categories.

To explore the complete findings, request a free sample of the report at https://www.rootsanalysis.com/reports/antiviral-drugs-market/request-sample.html

Market Overview
Viruses account for a disproportionate share of global mortality. According to the National Institutes of Health, infectious diseases cause approximately 52 million deaths annually, representing roughly one-third of all deaths worldwide. HIV alone is projected to cause 3 million deaths by 2030, per WHO estimates, necessitating sustained demand for long-term antiviral therapy. COVID-19 further demonstrated how quickly a novel pathogen can generate systemic pharmaceutical need, with remdesivir and other antivirals repurposed under emergency use before dedicated treatments received full approval.

The market now sits at an inflection point. Of the 220 known human-infecting viruses, only 10 currently have approved drug coverage, and approximately 80 approved antiviral drugs address that narrow subset. This gap between the breadth of viral threats and available therapeutics is generating sustained investment in novel drug development. More than 375 companies are actively developing over 420 early and late-stage antiviral medications globally, covering mechanisms from reverse transcriptase inhibition to host-targeting approaches. Recent transactions underscore the strategic intensity: in December 2025, Sanofi completed its USD 1.2 billion acquisition of Vicebio to gain preclinical antivirals targeting influenza and SARS-CoV-2, while Gilead Sciences received FDA approval in June 2025 for Yeztugo (lenacapavir), the first twice-yearly injectable for HIV pre-exposure prophylaxis.

The pipeline is not concentrated in one segment. Across therapeutic targets from HIV to hepatitis B, respiratory syncytial virus, and emerging pathogens, clinical activity spans phase I through phase III. Gene therapy and RNA-based approaches are entering clinical evaluation, adding mechanistic diversity to a field that has historically depended on small-molecule drugs.

Key Growth Drivers
Persistent HIV Burden Sustaining Long-Term Drug Demand. HIV remains the single largest indication within the antiviral drugs market, commanding 38% of market share. Because HIV requires lifetime antiviral therapy, the patient base generates recurring, predictable demand. New formulations such as long-acting injectables are expanding adherence options and creating fresh commercial opportunities within an already established therapy category.

Post-COVID Research Investment Sustaining the Pipeline. The pandemic accelerated antiviral R&D timelines and drew significant public and private capital into the sector. That momentum has not dissipated. As of the most recent data, 182 active clinical trials are targeting COVID-19 and long COVID syndromes, with post-COVID conditions creating new indications for antivirals beyond acute infection management.

Host-Targeting Therapies Broadening the Drug Development Horizon. Virus-targeting drugs account for 77% of current market revenue, but host-targeting therapies are gaining attention for their ability to address broad-spectrum viral activity and reduce resistance risk. By targeting cellular pathways that viruses exploit for replication, rather than viral proteins that mutate, host-directed therapies offer a more durable mechanism of action and are increasingly being combined with existing antivirals.

AI-Assisted Drug Discovery Compressing Development Timelines. Startups and established players are integrating artificial intelligence into antiviral drug discovery. Estonia-based Nora AI, for example, has built a platform specifically for AI-driven antiviral evaluation. These tools are helping developers screen candidates faster and identify combination therapy candidates with greater precision, lowering the cost per successful program.

Combination Therapy Adoption Gaining Commercial Traction. Monotherapy still holds 79% of market share, but combination therapy is the faster-growing segment, advancing at a CAGR of 7.4%. Clinical data consistently demonstrates higher success rates for combination regimens, particularly in HIV and hepatitis C, and cost-effectiveness analyses are supporting broader formulary adoption across payer systems.

Market Segmentation
By mechanism of action, the antiviral drugs market divides across fusion inhibitors, DNA polymerases, protease inhibitors, reverse transcriptase inhibitors, and others. Reverse transcriptase inhibitors lead this segmentation with 34% of market revenue, driven by their central role in HIV and hepatitis C treatment protocols. By target indication, HIV infection holds the dominant position at 38% share, with coronavirus treatments accounting for 15.7%. By drug target, virus-directed compounds generate 77% of revenue while host-targeting drugs grow at 6.1% CAGR. Monotherapy leads by therapy type at 79% share, while combination therapy expands at 7.4% CAGR.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/antiviral-drugs-market/request-quote.html

Regional Insights
North America holds 46% of the global antiviral drugs market and will maintain its leadership through 2035. The United States drives this position through a combination of the FDA's active approvals pipeline, the largest healthcare budget among individual nations, and a dense network of academic research institutions focused on infectious disease. Nearly 75% of companies developing antiviral drugs are headquartered in North America, giving the region a structural advantage in both development capacity and market access.

Asia Pacific is the fastest-growing region, projected to advance at 8.4% CAGR during the forecast period. A large and growing population base, expanding healthcare infrastructure, rising prevalence of viral infections including hepatitis B and influenza, and increasing government healthcare spending are the primary factors behind this acceleration. Markets including India, China, and Southeast Asia are absorbing greater volumes of approved antivirals while also developing domestic manufacturing and R&D capabilities.

Competitive Landscape
Key companies profiled in the antiviral drugs market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Genentech, Gilead Sciences, GlaxoSmithKline (GSK), Johnson & Johnson, Merck, Novartis, Pfizer, Roche, and ViiV Healthcare. The market blends well-capitalized pharmaceutical majors with a growing number of biotech startups, particularly in AI-driven discovery. Competition centers on IP breadth, pipeline depth, and the ability to secure regulatory approval across multiple geographies. M&A activity is intensifying as large players seek to acquire late-stage assets rather than build early-stage programs internally, as evidenced by Sanofi's Vicebio deal and Basilea Pharmaceutica's in-licensing of a Phase III-ready asset from VenatoRx.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/antiviral-drugs-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.